OBJECTIVE: To investigate the impact of probiotic Bifidobacterium longum ssp. infantis on the fecal microbiota and plasma cytokines in neonates with congenital heart disease. STUDY DESIGN: Sixteen infants with congenital heart disease were randomly assigned to receive either B. infantis (4.2 Â 10 9 colonyforming units two times daily) or placebo for 8 weeks. Stool specimens from enrolled infants and from six term infants without heart disease were analyzed for microbial composition. Plasma cytokines were analyzed weekly in the infants with heart disease. RESULTS: Healthy control infants had increased total bacteria, total Bacteroidetes and total bifidobacteria compared to the infants with heart disease, but there were no significant differences between the placebo and probiotic groups. Plasma interleukin (IL)10, interferon (IFN)g and IL1b levels were transiently higher in the probiotic group. CONCLUSION: Congenital heart disease in infants is associated with dysbiosis. Probiotic B. infantis did not significantly alter the fecal microbiota. Alterations in plasma cytokines were found to be inconsistent.
INTRODUCTION
Necrotizing enterocolitis (NEC) is predominantly a disease of premature infants. Among term infants, the prevalence of NEC has been estimated at 1 in 20 000 live births. 1 Congenital heart disease (CHD) is one of the most consistent risk factors for NEC in term infants. In two case series, about one-third of term infants with NEC had CHD. 1, 2 Among term infants with CHD requiring surgery in the neonatal period, the incidence of NEC has been reported to be 3-7%, which is similar to the incidence among premature infants. 3, 4 Mortality rates among infants with CCHD who develop NEC, however, may be even greater than in premature infants, 5, 6 with one study reporting mortality as high as 71%. 7 In premature infants, primary risk factors for NEC include immaturity, enteral feeding and atypical development of the intestinal microbiota (dysbiosis). 8 In premature infants, the most promising interventions in prevention of NEC include human milk 9 and probiotics. 10 Probiotics have been shown to decrease gene expression of proinflammatory cytokines 11 and to alter the intestinal microbiota. 12 Whether the pathophysiology of NEC in term infants with CHD is similar to that in premature infants is unknown.
We performed a pilot study of probiotic administration to term infants scheduled for cardiac surgery within the first weeks of life. Our hypotheses were that term infants with CHD would have a markedly different intestinal microbiota than healthy term infants and that administration of probiotic bifidobacteria to term infants with CHD would alter the intestinal microbiota and the levels of plasma cytokines.
METHODS
This trial was performed at UC Davis Children's Hospital in Sacramento (CA, USA) from August 2009 to December 2010 following approval from the Institutional Review Board and registration at clinicaltrials.gov. Eligible infants included those with gestational age at least 34 weeks, CHD requiring repair in the neonatal period and absence of congenital gastrointestinal anomalies. Following informed consent from the parents, infants were randomly assigned by the UC Davis Investigational Pharmacy to receive either 4.2 Â 10 9 colony-forming units of Bifidobacterium longum ssp. infantis ATCC 15697 or a placebo two times daily for 8 weeks or until death or discharge if sooner.
The probiotic strain was chosen based on its genetic capacity to digest human milk oligosaccharides, an advantage in colonizing the neonatal intestinal tract. 13 To avoid the drawbacks of over-the-counter probiotic products (for example, inconsistent composition and viability), 14 the probiotic strain was grown by a food-grade commercial facility (Culture Systems, Mishawaka, IN, USA) and stored at À 80 1C. Purity and number of viable bacteria was confirmed every 6 months by culture techniques. The placebo was a dilute formulation of Pregestimil powder (Mead Johnson, Glenview, IL, USA) without significant caloric value. The investigators, clinical research coordinator, caregivers and parents were blinded as to group of assignment.
Feces were obtained from a soiled diaper before the first dose of the study product and then weekly thereafter when possible. Fecal samples were refrigerated overnight, transported on dry ice and stored at À 80 1C. A measure of 1 ml of blood was obtained at enrollment and then weekly for 5 weeks when possible. The blood was centrifuged at 3000 r.p.m. for 15 min and the plasma frozen at À 80 1C.
The healthy comparison group consisted of six term breast-fed infants. None had CHD, required hospitalization or were treated with antibiotics or probiotics during the study period. Stool samples were obtained from a soiled diaper by the parents at regular intervals and kept on ice until transport within 12 h and storage at À 80 1C.
DNA extraction
Bacterial genomic DNA was extracted from stool samples as previously described with a few modifications. 15 Briefly, frozen stool was thawed and centrifuged (8000 g for 5 min at room temperature). The fecal pellet was rinsed two times with phosphate-buffered saline and then resuspended in 200 ml lysis buffer (2 mM EDTA, 1.2% Triton X-100, 20 mM Tris-HCl, pH 8.0) with freshly added 40 mg ml À 1 lysozyme. The solution was incubated at 37 1C for 30 min. Buffer ASL from QIAamp DNA Stool Mini Kit (Qiagen, Valencia, CA, USA) was added to equal 2.0 ml, vortexed until thoroughly mixed and then homogenized by bead-beating in a FastPrep-24 Instrument (MP Biomedicals, Solon, OH, USA) for 2 min at 6.5 m s À 1 . The homogenate was incubated for 5 min at 95 1C, vortexed and centrifuged at 13 000 g for 1 min to pellet stool particles. DNA in the supernatant was purified with the Qiagen Stool Mini Kit. qPCR SYBR green and TaqMan quantitative real-time PCR (qPCR) assays were performed on a 7500 Fast Real-Time PCR System (Applied Biosystems, Carlsbad, CA, USA) with primers specific for universal eubacteria and bifidobacteria. Universal eubacteria SYBR green assays contained 10 ml of 2 Â Takara Perfect Real-Time master mix (Clontech Laboratories, Mountain View, CA, USA), 6 ml water, 400 nM of forward and reverse primers (all primers listed in the Supplementary Information Table A) and 2 ml diluted 1:100 genomic DNA with cycling conditions as described previously. 16 Bifidobacteria TaqMan qPCR assays contained 12.5 ml 2Â TaqMan Universal PCR master mix (Applied Biosystems), 300 nM of forward and reverse primers, 150 nM TaqMan probe, 3.75 ml water and 2.5 ml diluted 1:100 genomic DNA 17 with cycling conditions as described previously. 16 All reactions were carried out in triplicate with a nontemplate control. TRFLP analysis of the fecal microbiota PCR amplification was performed in 50-ml reactions containing 1-5 ng of DNA template, 25 ml 2Â Promega GoTaq Green Master Mix (Promega, Madison, WI, USA), 1 mM MgCl 2 and 2 pmol of each primer. 18, 19 Each PCR was performed in triplicate and the products combined before purification. The PCR conditions were an initial denaturation at 95 1C for 2 min, followed by 30 cycles of denaturation at 95 1C for 30 s, annealing at 50 1C for 30 s and extension at 72 1C for 2 min, with a final extension at 72 1C for 5 min.
A focused terminal restriction fragment length polymorphism (TRFLP) of non-clostridial Firmicutes was performed as described. 20 PCR conditions consisted of an initial denaturation at 95 1C for 5 min, followed by 30 cycles of denaturation at 95 1C for 45 s, annealing at 66 1C for 30 s and extension at 72 1C for 45 s, with a final extension at 72 1C for 5 min.
PCR products were analyzed by electrophoresis and purified using the QIAquick PCR Purification Kit (Qiagen, Valencia, CA, USA). All 16S-TRFLP amplicons were digested using the enzymes AluI, MspI, HaeIII and HhaI. Focused TRFLP amplicons were digested using the enzymes MseI, Hpy188I and Hpy188III. Next, 1.5 ml of the digestion mixture was used for fragment analysis and traces were visualized with the program Peak Scanner v.1.0 (Applied Biosystems). Peak filtration and clustering analyses were performed with R software (http://cran.r-project.org), using published program scripts and analysis protocols. 21 Taxonomic assignments of operational taxonomic units were based on comparison to an in silico digest database generated by the virtual digest tool from MiCA 22 of good-quality 16S rRNA gene sequences compiled by the Ribosomal Database Project Release. 23, 24 Two infants in the placebo group were not fed enterally during the study period. 
Cytokine analysis
Plasma cytokines were quantified using high-sensitivity human multiplexing bead immunoassays (Millipore Corporation, St Charles, MO, USA) based on a sandwich immunoassay utilizing the Luminex fluorescentbead-based technology following established protocols. 25 Briefly, 50 ml of plasma were incubated with antibody-coupled beads. After a series of washes, a biotinylated detection antibody was added followed by streptavidin-phycoerythrin. The bead sets were analyzed using a flowbased Luminex 100 suspension array system (Bio-Plex 200; Bio-Rad Laboratories, Hercules, CA, USA). Unknown sample cytokine concentrations were calculated by Bio-Plex Manager software (Bio-Rad Laboratories) using a standard curve derived from the known reference cytokine concentrations. A five-parameter model was used to calculate final concentrations.
Statistical analysis
Using QIIME software (http://qiime.org), multidimensional summary measures of the microbial composition of the fecal samples analyzed by 16S-TRFLP were derived and visualized in a reduced number of dimensions via a three-dimensional principal coordinate analysis plot. 26 Shannon diversity indices were calculated from the TRFLP data.
qPCR and cytokine data were log transformed and analyzed in STATA (version 9, 2007, STATA Corp, College Station, TX, USA) using repeatedmeasures analysis of variance (ANOVA). For data that did not approximate a normal distribution after log transformation, the non-parametric Kruskal-Wallis test was used at specific time points. For the baseline and combined qPCR data and the combined Shannon diversity indices, standard one-way ANOVA with Scheffe's test for differences between groups was used. For the qPCR data, readings of zero were presumed to represent 1 Â 10 4 , the lower limit of detection. Given that this pilot study was designed to generate hypotheses rather than test them, we report P-values o0.1 as being of interest for possible future testing.
RESULTS
Sixteen infants with CHD were enrolled in the study. Two of the infants were removed from the study before receiving the study product, one because of transfer to another facility (placebo group) and one at the request of the parents (probiotic group). Baseline specimens, demographic and clinical data were included for both on an intention-to-treat basis. A summary of patient details is provided in Table 1 , with patient-specific details in the Supplementary Information Table B ). The groups were similar, except for age at enrollment.
TRFLP and qPCR are complementary techniques, with the former providing an overview of all identifiable bacteria and the latter providing more precise quantification of total bacteria and specific taxa. Figure 1 presents the mean percentages of bacterial phyla by TRFLP for each group over time. Bacteroidetes were more common in the healthy control infants than the CHD infants at baseline, weeks 1-6, and weeks 7 and greater (Kruskal-Wallis P ¼ 0.036, 0.068 and 0.041). Actinobacteria showed the same pattern (Kruskal-Wallis P ¼ 0.017, 0.023 and 0.035 at the same time points). Firmicutes were more common in infants with CHD, but only at the middle time points (weeks 1-6, Kruskal-Wallis P ¼ 0.052). No significant differences were noted between the placebo and probiotic groups. The TRFLP data for each individual infant at the class/order level are presented in the Supplementary Information Figure A . The phylum Firmicutes includes the Gram-positive classes Clostridia, Bacilli and Negativicutes. To characterize the non-clostridial Firmicutes, focused TFRLP analysis was performed for each specimen for 3 of the control infants and 14 of the infants with heart disease. All groups showed a predominance of streptococci with no detectable lactobacilli. A trend towards decreased enterococci in the healthy controls did not reach statistical significance (Supplementary Information: group comparison in Supplementary Figure B , with individual analyses in Supplementary Table C ). Figure 2 is the principal coordinate analysis of the TRFLP data. Each circle represents one specimen with increased distance between circles reflective of greater differences in microbial composition. The Shannon diversity indices (mean (s.d.)) were 2.3 (0.22) for the infants without CHD, 2.1 (0.40) for the probiotic group and 1.92 (0.51) for the placebo (ANOVA P ¼ 0.24). Figure 3 presents the mean qPCR data for total bacteria, total Enterobacteriaceae and total bifidobacteria for each group over time. The healthy control infants without CHD had greater total bacteria, total Enterobacteriaceae and total bifidobacteria at baseline and in the combined non-baseline specimens (Figure 4) . The individual qPCR analyses for each infant are presented in the Supplementary Information Figure C) . Primers specific for B. longum were used to assess what proportion of fecal bifidobacteria are the same species as the ingested probiotic. Among the infants receiving the probiotic, 93% of the Figure 4 . Box plots of quantitative real-time PCR (qPCR) data for each group at baseline and all subsequent time periods combined. The Y axis is log-transformed copies of the 16S rRNA gene per gram of stool. Total bacteria (baseline analysis of variance (ANOVA) P ¼ 0.03 (Scheffe P ¼ 0.07 probiotic vs control and P ¼ 0.06 placebo vs control); weeks 1-11 ANOVA P ¼ 0.001 (Scheffe P ¼ 0.002 placebo vs control)). Total Enterobacteriaceae (baseline ANOVA P ¼ 0.003 (Scheffe P ¼ 0.006 probiotic vs control and P ¼ 0.01 placebo vs control); weeks 1-11 ANOVA P ¼ 0.07 (Scheffe P ¼ 0.07 probiotic vs control)). Total bifidobacteria (baseline ANOVA P ¼ 0.02 (Scheffe P ¼ 0.02 probiotic vs control and P ¼ 0.05 placebo vs control); weeks 1-11 ANOVA P ¼ 0.008 (Scheffe P ¼ 0.04 probiotic vs control and P ¼ 0.01 placebo vs control)).
bifidobacteria identified were B. longum, whereas among the infants receiving placebo, 72% were B. longum. Whether this represents cross-contamination as has been demonstrated in other probiotic studies 27 is unclear. The mean percentage of bifidobacteria identified as B. longum from three of the control infants (B, C and D) were 43%, 58% and 0%, respectively. Figure 5 presents levels of four cytokines in the CHD infants. Differences between groups over time were significant for interferon (IFN)g (P ¼ 0.007) and interleukin (IL)1b (P ¼ 0.04), with the following differences at individual weeks: IFNg week 1 (P ¼ 0.08), IL1b week 3 (P ¼ 0.06) and IL10 week 2 (P ¼ 0.06). No trends were noted for tumor necrosis factor-a or IL8 (data not shown).
DISCUSSION
In the premature infant, NEC is common and devastating. The pathophysiology of this disease is incompletely understood. Major risk factors in the premature infant include degree of prematurity, formula feeding and dysbiosis. 8 Other possible risk factors include red blood cell transfusion 28 and maternal smoking. 29 Prematurity remains the most prominent predictor of NEC risk and is likely related to immaturity of multiple aspects of gastrointestinal mucosal immunity (including barrier integrity, signaling, proinflammatory responses, Paneth cell function, secretion of antimicrobial molecules, autophagy and apoptosis). [30] [31] [32] Four strands of evidence link dysbiosis and NEC in the premature infant. First, prolonged antibiotic exposure is associated with NEC. 33 Second, increased numbers of Gram-negative Enterobacteriaceae dominate the feces of NEC patients. 34, 35 Third, multiple clinical trials demonstrate decreased risk of NEC in premature infants receiving probiotics. 36 Fourth, acid suppression changes the fecal microbiota and increases risk of developing NEC in premature infants. 37, 38 In the term infant, NEC is relatively rare. Among this population, the association between CHD and NEC is well established; however, given the relatively small number of cases of NEC in term infants with heart disease at any single institution, the pathophysiology of this form of NEC is unexplored. 39 In particular, it is unknown whether formula feeding, dysbiosis, transfusion, maternal smoking, dysfunction of mucosal immunity or alterations in oxygenation or perfusion of the intestine are significant risk factors in this population.
The purpose of this pilot study was to generate preliminary data to begin to address two hypotheses: that infants with CHD would demonstrate significant intestinal dysbiosis and that probiotic B. infantis would partially 'normalize' the microbiota (that is, shift the composition towards that of the healthy infant). This study supports the first hypothesis in that infants with CHD develop an altered fecal microbiota most marked by decreased total bacteria, decreased Actinobacteria (predominantly bifidobacteria), decreased Bacteroidetes, decreased Enterobacteriaceae and increased Firmicutes (predominantly enterococci). However, no significant differences in the composition of the fecal microbiota were noted between the two groups of infants with heart disease, suggesting against our second hypothesis. The lack of a significant increase in fecal bifidobacteria with probiotic treatment in this population differs from observations with this organism in hospitalized premature infants (manuscript submitted). It is possible that other influences on the intestinal microbiota including timing and type of enteral feeding, antibiotic treatment, inhibition of acid suppression and hypoxia and/or ischemia play such a large role in shaping the microbiota that the influence of the probiotic is minimal.
Several Gram-negative Enterobacteriaceae have been shown to trigger an inflammatory response in the intestinal mucosa and then out-compete the commensal organisms in this proinflammatory environment. 40 One possible mechanism for the observed anti-inflammatory effects of probiotics is the displacement of this proinflammatory population. We included analysis of plasma cytokines to explore the hypothesis that alterations in the microbiota were associated with changes in key cytokines implicated in NEC. As we were unable to observe significant changes in the microbiota related to the probiotic administration, this hypothesis remains untested in this population.
Pilot studies provide preliminary data to determine sample size and/or justify larger definitive studies. NEC occurs at a younger age in term infants than premature infants, suggesting that a Figure 5 . Box plots of plasma cytokines for the two groups of infants with congenital heart disease (CHD) for each study week. White boxes, probiotic group; gray boxes, placebo group. Y axes are pg ml À 1 . IFN, interferon; IL, interleukin.
beneficial effect of probiotics would need to manifest quickly. On the basis of changes seen after 1 week of probiotic or placebo in this study, sample size calculations for definitive studies of several possible outcomes are summarized in Table 2 . A clinical trial of probiotics in term infants with CHD to decrease risk of NEC would require several hundred infants in each arm; however, a moderatesized trial to assess short-term increases in fecal bifidobacteria or beneficial changes in cytokines appears justifiable. .0 Â 10 9 (5.3 Â 10 9 ) 5.5 Â 10 6 (1.0 Â 10 7 ) 1 9
Abbreviations: CHD, congenital heart disease; IL, interleukin; TNF, tumor necrosis factor.
